REGISTER

Overview

Has a client ever said to you, “Can you tell if my dog has cancer from the blood work”?

There are multiple clinical scenarios where non-invasive cancer detection with just a blood draw would be a benefit for our patients and their families. The introduction of blood-based cancer detection, known as “liquid biopsy”, now allows veterinarians to screen asymptomatic, high-risk patients for cancer, and determine if cancer is present in patients for which cancer is suspected (due to history, exam, or workup).

This session will focus on how next-generation sequencing (NGS) of cell-free DNA (cfDNA) in blood can be used to detect genomic abnormalities that indicate the presence of cancer in dogs. The clinical applications of liquid biopsy will be examined, including both pre- and post-diagnosis use cases.

Program Agenda

• The science behind liquid biopsy testing: cancer genomics
• The technology behind liquid biopsy testing: next-generation sequencing
• The clinical uses of liquid biopsy testing: AKA “use cases”
• The evidence that liquid biopsy testing works in dogs: proof of concept and clinical validation

Learning Objectives

• Identify key biological principles in the development of canine cancer
• Explain how genomics can be leveraged to aid in the early identification and characterization of cancer in dogs
• Evaluate the benefits and limitations of liquid biopsy testing
• Define scenarios in which liquid biopsy testing may provide clinical utility

Accreditation/Credit Designation

This program has been approved for 1 hour of continuing education credit in jurisdictions that recognize RACE approval.

Acknowledgment of Commercial Support

This webinar is sponsored by PetDx.

REGISTER